ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Unveiling the therapeutic potential of Farnesol against Parkinson's disease: insights from molecular Docking and animal studies.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) is a chronic neurodegenerative disorder that progressively worsens over an individual's lifetime. Current treatments primarily address the symptoms rather than the underlying cause of the disease, and many patients report adverse side effects from the medications used. Nature offers a wealth of medicinal plants, among which Ocimum tenuiflorum stands out for its potential to treat various health issues.
objectiveThe objective of the study is to identify an effective phytochemical from Ocimum tenuiflorum using in silico and in vivo methods for the management of PD.
methodsMolecular docking was employed to identify potential phytochemicals in Ocimum tenuiflorum that target the mTOR pathway. Farnesol was chosen for further evaluation based on its docking score, blood-brain barrier permeability, and pharmacokinetic properties. In vivo studies were carried out using rotenone-induced PD models in mice, and the effects of farnesol on behavioral changes, oxidative stress, and histopathological alterations were examined.
resultsFarnesol showed a high docking score and the ability to cross the blood-brain barrier. In vivo studies revealed that farnesol treatment enhanced locomotor activity, lowered cataleptic scores, and increased antioxidant enzyme activity (SOD) in the brain. The strongest antioxidant effect was achieved by the high dose, which brought the levels of MDA and SOD near to the control 8.3% and 95.4% respectively, as compared to the disease group. Additionally, farnesol decreased lipid peroxidation levels and protected against neuronal damage in the substantia nigra region.
conclusionFarnesol exhibits significant neuroprotective effects in rotenone-induced PD models, suggesting its potential as a therapeutic candidate for managing PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.